The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

被引：17

作者：

Ferraldeschi, Roberta ^{[1
,2
]}

Newman, William G. ^{[2
]}

机构：

[1] Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England

[2] Univ Manchester, MAHSC, St Marys Hosp, Genet Med, Oxford Rd, Manchester M13 9WL, Lancs, England

来源：

PHARMACEUTICALS | 2010年 / 3卷 / 04期

关键词：

tamoxifen; CYP2D6; genotyping; breast cancer;

D O I：

10.3390/ph3041122

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in CYP2D6 influence the clinical outcomes of patients treated with adjuvant tamoxifen. Here, we review the existing data relating CYP2D6 genotypes to tamoxifen efficacy.

引用

页码：1122 / 1138

页数：17

共 63 条

[21] Tamoxifen, Antidepressants, and CYP2D6: The Conundrum Continues [J].

Holzman, David .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (20) :1370-1371

[22] CYP2D6 and tamoxifen: DNA matters in breast cancer [J].

Hoskins, Janelle M. ;

Carey, Lisa A. ;

Mcleod, Howard L. .

NATURE REVIEWS CANCER, 2009, 9 (08) :576-586

[23] Tamoxifen: the drug that came in from the cold [J].

Hughes-Davies, L. ;

Caldas, C. ;

Wishart, G. C. .

BRITISH JOURNAL OF CANCER, 2009, 101 (06) :875-878

[24] Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity [J].

Ingelman-Sundberg, M .

PHARMACOGENOMICS JOURNAL, 2005, 5 (01) :6-13

[25] CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment [J].

Jin, Y ;

Desta, Z ;

Stearns, V ;

Ward, B ;

Ho, H ;

Lee, KH ;

Skaar, T ;

Storniolo, AM ;

Li, L ;

Araba, A ;

Blanchard, R ;

Nguyen, A ;

Ullmer, L ;

Hayden, J ;

Lemler, S ;

Weinshilboum, RM ;

Rae, JM ;

Hayes, DF ;

Flockhart, DA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01) :30-39

[26] Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen [J].

Johnson, MD ;

Zuo, H ;

Lee, KH ;

Trebley, JP ;

Rae, JM ;

Weatherman, RV ;

Desta, Z ;

Flockhart, DA ;

Skaar, TC .

BREAST CANCER RESEARCH AND TREATMENT, 2004, 85 (02) :151-159

[27] MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTI-ESTROGENIC ACTIVITY [J].

JORDAN, VC ;

COLLINS, MM ;

ROWSBY, L ;

PRESTWICH, G .

JOURNAL OF ENDOCRINOLOGY, 1977, 75 (02) :305-316

[28] Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study [J].

Kelly, Catherine M. ;

Juurlink, David N. ;

Gomes, Tara ;

Duong-Hua, Minh ;

Pritchard, Kathleen I. ;

Austin, Peter C. ;

Paszat, Lawrence F. .

BMJ-BRITISH MEDICAL JOURNAL, 2010, 340 :355

[29] Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen [J].

Kimmick, GG ;

Lovato, J ;

McQuellon, R ;

Robinson, E ;

Muss, HB .

BREAST JOURNAL, 2006, 12 (02) :114-122

[30]

Kitoyani K., 2010, J CLIN ONCOL

← 1 2 3 4 5 6 7 →